// App-Quantinova.ai

P2-05-02 : Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis

Researchers

Presenter

  • W Janni

Principal Investigators

  • B Rack

  • L Häberle

  • TWP Friedl

  • H Tesch

  • R Lorenz

  • B Jäger

  • T Fehm

  • V Müller

  • A Schneeweiß

  • W Lichtenegger

  • J Blohmer

  • MW Beckmann

  • C Scholz

  • K Pantel

  • E Trapp

  • PA Fasching

Medical Centers

  • Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany

  • University of Munich, Munich, Germany

  • Hamato-Onkologische Praxis Frankfurt, Frankfurt, Germany

  • University Clinic Heidelberg, Heidelberg, Germany

  • Heinrich-Heine-Universitat, Dusseldorf, Germany

  • Charite University Hospital, Berlin, Germany.

  • University of Ulm, Ulm, Germany

  • University of Erlangen-Nuernberg, Erlangen, Germany

  • Onkologische Praxisklinik, Braunschweig, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Body mass index

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved